Alen Ostojić

Dr. Alen Ostojić

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2011 in Future Oncology
Verified
Journal Article
Closed access
AOAlen Ostojić
Alen Ostojić
RVRadovan Vrhovac
Radovan Vrhovac
SVSrdan Verstovsek
Srdan Verstovsek
Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use. Its major cellular and systemic effects are proliferation inhibition, apoptos...

1 August 2012 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JRJasleen Randhawa
Jasleen Randhawa
AOAlen Ostojić
Alen Ostojić
RVRadovan Vrhovac
Radovan Vrhovac
EAEhab Atallah
Ehab Atallah
SVSrdan Verstovsek
Srdan Verstovsek
Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on patients’ quality of life. It may also be present in patients with advanced polycythemia vera (PV) or essential thrombocythemia (ET). Until recently, none of the therapies used to treat MF were particularly effective in reducing splenomegaly. The discovery of an activating Janus kinase 2 (JAK2) activating mutation (JAK2V617F) that is present in almost all patients with PV and in about 50-60 % of patients with ET and PMF led to the initiation of several trials investigating the clinical effectiveness of various JAK2 (or JAK1/JAK2) inhibitors for the treatment of patients with ET, PV, and MF. Some of these trials have documented significant clinical benefit of JAK inhibitors, particularly in terms of regression of splenomegaly. In November 2011, the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET MF. This review discusses current therapeutic options for splenomegaly associated with primary or secondary MF and the treatment potential of the JAK inhibitors in this setting.

1 March 2012 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
SVSrdan Verstovsek
Srdan Verstovsek
AOAlen Ostojić
Alen Ostojić
RVRadovan Vrhovac
Radovan Vrhovac
Peer reviewed article authored by (Ostojic A, Vrhovac R, Verstovsek S). Read article or submit your manuscript for publishing.

18 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
LCLauren M. Curtis
Lauren M. Curtis
AOAlen Ostojić
Alen Ostojić
DVDavid J. Venzon
David J. Venzon
NHNoa G. Holtzman
Noa G. Holtzman
FPFilip Pirsl
Filip Pirsl
SPSteven Z. Pavletic
Steven Z. Pavletic
Steroid-refractory chronic graft-versus-host disease (cGVHD) is a therapeutic challenge. Sclerotic skin manifestations are especially difficult to treat. We conducted a randomized phase 2 clinical trial (#NCT01688466) to determine the safety, efficacy, and preferred dose of pomalidomide in persons with moderate to severe cGVHD unresponsive to corticosteroids and/or subsequent lines of therapy. Thirty-four subjects were randomized to receive pomalidomide 0.5 mg per day orally (n = 17; low-dose cohort) or 2 mg per day at a starting dose of 0.5 mg per day increasing to 2 mg per day over 6 weeks (n = 17; high-dose cohort). The primary endpoint was overall response rate (ORR) at 6 months according to the 2005 National Institutes of Health cGVHD Response Criteria. Thirty-two patients had severe sclerotic skin and received a median of 5 (range, 2-10) previous systemic therapies. ORR was 47% (95% confidence interval, 30-65) in the intention-to-treat analyses. All were partial responses, with no difference in ORR between the cohorts. ORR was 67% (45%-84%) in the 24 evaluable subjects at 6 months. Nine had improvement in National Institutes of Health joint/fascia scores (P = .018). Median change from the baseline in body surface area involvement of skin cGVHD was −7.5% (–10% to 35%; P = .002). The most frequent adverse events were lymphopenia, infection, and fatigue. Eight subjects in the high-dose cohort had dose decreases because of adverse events. There was 1 death in the low-dose cohort from bacterial pneumonia. Our data indicate antifibrotic effects of pomalidomide and possible association with increases in concentrations of blood regulatory T-cell and interleukin-2. Pomalidomide 0.5 mg per day is a safe and effective therapy for advanced corticosteroid-refractory cGVHD.

15 August 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
NHNoa G. Holtzman
Noa G. Holtzman
LCLauren M. Curtis
Lauren M. Curtis
RSRachel B. Salit
Rachel B. Salit
BSBrian C. Shaffer
Brian C. Shaffer
FPFilip Pirsl
Filip Pirsl
SPSteven Z. Pavletic
Steven Z. Pavletic
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative setting, its effects after reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted lymphodepletion chemotherapy followed by a RIC allo-HSCT using peripheral blood stem cells from unrelated donors. Patients were randomized to 2 GVHD prophylaxis arms: alemtuzumab and cyclosporine (AC; n = 44) or tacrolimus, methotrexate, and sirolimus (TMS; n = 39), with the primary end point of cumulative incidence of severe cGVHD. The incidence of severe cGVHD was lower with AC vs TMS prophylaxis at 1- and 5-years (0% vs 10.3% and 4.5% vs 28.5%; overall, P = .0002), as well as any grade (P = .003) and moderate-severe (P < .0001) cGVHD. AC was associated with higher rates of grade 3 to 4 infections (P = .02) and relapse (52% vs 21%; P = .003) with no difference in 5-year GVHD-free-, relapse-free-, or overall survival. AC severely depleted naïve T-cell reconstitution, resulting in reduced T-cell receptor repertoire diversity, smaller populations of CD4Treg and CD8Tscm, but a higher ratio of Treg to naïve T-cells at 6 months. In summary, an alemtuzumab-based regimen successfully reduced the rate and severity of cGVHD after RIC allo-HSCT and resulted in a distinct immunomodulatory profile, which may have reduced cGVHD incidence and severity. However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. This trial was registered at www.ClinicalTrials.gov as #NCT00520130.

1 August 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
AOAlen Ostojić
Alen Ostojić
DSDubravka Sertic
Dubravka Sertic
PRPavle Roncevic
Pavle Roncevic
ZPZinaida Peric
Zinaida Peric
PGPaula Granic
Paula Granic
DNDamir Nemet
Damir Nemet